Factor XI Inhibitor

Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research.

ISIS 416858, a single-stranded antisense oligodeoxynucleotide, is a potent and selective inhibitor of FXI mRNA expression.

Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC₅₀ of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC₅₀ of 59 pM. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis.

BMS-962212 hydrochloride is a selective coagulation factor XIa inhibitor and acute antithrombotic agent. BMS-962212 hydrochloride can be used in the research of thrombosis.

FAM labled Vortosiran sodium (RBD4059) a FAM labled Vortosiran sodium. Vortosiran sodium is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran sodium shows potent inhibitory activity against mouse FXI transcripts with an IC₅₀ of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC₅₀ of 59 pM. Vortosiran sodium exhibits antithrombotic activity without impairing hemostatic function. Vortosiran sodium can be used in research related to intravascular thrombosis.

MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research.

Vortosiran (RBD4059) sodium is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran sodium shows potent inhibitory activity against mouse FXI transcripts with an IC₅₀ of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC₅₀ of 59 pM. Vortosiran sodium exhibits antithrombotic activity without impairing hemostatic function. Vortosiran sodium can be used in research related to intravascular thrombosis.

FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with K_i values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases.

Neutrophil elastase-IN-7 is a human neutrophil elastase inhibitor with an IC₅₀ of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against multiple coagulation proteins, with IC₅₀ values of 8.2, 12.7, 1.2 and 5.7 μM against thrombin, FXa, FXIa and FXIIIa, respectively. Neutrophil elastase-IN-7 can be used in the research of cardiopulmonary diseases and inflammatory diseases.

Cy3 labled Vortosiran (RBD4059) sodium is a Cy3 labled Vortosiran sodium. Vortosiran (RBD4059) sodium is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran sodium shows potent inhibitory activity against mouse FXI transcripts with an IC₅₀ of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC₅₀ of 59 pM. Vortosiran sodium exhibits antithrombotic activity without impairing hemostatic function. Vortosiran sodium can be used in research related to intravascular thrombosis.

FXIa-IN-17 (Compound FE12) is a selective FXIa inhibitor with an IC₅₀ of 4.4 nM. FXIa-IN-17 effectively inhibits thrombus formation.

Factor XI-IN-2 is a Factor XI activation inhibitor with an IC₅₀ of 20 nM. Factor XI-IN-2 does not directly inhibit the enzymatic activity of FXIa, but specifically binds to the FXI enzyme precursor and allosterically inhibits the process by which it is activated by FXIIa. Factor XI-IN-2 inhibits thrombosis in the rabbit arteriovenous (AV) shunt thrombosis model. Factor XI-IN-2 can be used for the study of antithrombus.